The National Institutes of Health recently unveiled a collaborative program that will match researchers with a selection of pharmaceutical industry compounds to help scientists explore new treatments for patients. NIH’s new National Center for Advancing Translational Sciences (NCATS) has partnered initially with Pfizer, AstraZeneca, and Eli Lilly and Company which have agreed to make dozens of their compounds available for this initiative’s pilot phase.
NIH Launches Collaborative Program, Matches Researchers with Compounds to Explore New Treatments
Evidence of Basis for Caregiving Impulse Seen in NIH Brain Imaging Study
Distinct patterns of activity, which may indicate a predisposition to care for infants, appear in the brains of adults who view an image of an infant face, even when the child is not theirs, according to a study by researchers at the National Institutes of Health and in Germany, Italy, and Japan. Seeing images of infant faces appeared to activate in the adult’s brains circuits that reflect preparation for movement and speech as well as feelings of reward.
Bilinguals Switch Tasks Faster than Monolinguals
Children who grow up learning to speak two languages are better at switching between tasks than are children who learn to speak only one language, according to a study funded in part by the National Institutes of Health. However, the study also found that bilinguals are slower to acquire vocabulary than are monolinguals, because bilinguals must divide their time between two languages while monolinguals focus on only one.
NIH and Lilly Collaborate, Aim to Make Drug Development Pipelines More Productive
Over the past decade, collaborative research efforts to support the discovery and development of medicines has increased dramatically. Last month, the National Institutes of Health and Eli Lilly and Company announced a new collaboration: they will generate a publicly available resource to profile the effects of thousands of approved and investigational medicines in a variety of advanced disease-relevant testing systems [1]. In-depth knowledge of the biological profiles of these medicines may enable researchers to better predict treatment outcomes, improve drug development, and lead to more specific and effective approaches.